Phillips-Medisize Corp. has acquired Medicom Innovation Partner, a provider of device strategy, product design and development services with particular focus on personal connected health drug delivery device options for the biopharma and specialty pharmaceutical markets. Terms of the transaction were not disclosed.
Through the acquisition, Phillips-Medisize expects to bolster its position in the drug delivery device market. Together, the combined company will have more than 500 engineers across facilities in Hudson, WI; Mountain View, CA; Hillegom, Netherlands; Struer, Denmark; Cambridge, United Kingdom; and Suzhou, China. The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable and inhalation device service sector for biopharma customers, including early device strategy, human factors engineering, product development, clinical production, full scale production and integrated supply chain management.
“This transaction is consistent with our strategic focus on serving the rapidly growing diabetes, biologics, specialty pharmaceutical and personalized oncology markets that need these products and reinforces our leading position in drug delivery device solutions,” Matt Jennings, chairman, CEO and president of Phillips-Medisize, said in a press statement. He added that Medicom’s 100+ technology accelerators, coupled with Phillips-Medisize’s scale in design to manufacturing of high to low volume production drug delivery devices, will result in increased speed to market.
Medicom will continue to be led by Morten Nielsen, CEO and Medicom, and Medicom’s existing management team, according to the press statement. Nielsen will report to Bill Welch, Phillips-Medisize’s chief technology officer and global head of preproduction services.